Heron Therapeutics (HRTX) Non-Current Debt: 2016-2025
Historic Non-Current Debt for Heron Therapeutics (HRTX) over the last 2 years, with Sep 2025 value amounting to $107.5 million.
- Heron Therapeutics' Non-Current Debt rose 332.93% to $107.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.5 million, marking a year-over-year increase of 332.93%. This contributed to the annual value of $25.0 million for FY2024, which is 3.14% up from last year.
- As of Q3 2025, Heron Therapeutics' Non-Current Debt stood at $107.5 million, which was up 326.32% from $25.2 million recorded in Q1 2025.
- Heron Therapeutics' Non-Current Debt's 5-year high stood at $107.5 million during Q3 2025, with a 5-year trough of $24.0 million in Q3 2023.
- For the 3-year period, Heron Therapeutics' Non-Current Debt averaged around $35.0 million, with its median value being $24.7 million (2024).
- Data for Heron Therapeutics' Non-Current Debt shows a peak YoY soared of 332.93% (in 2025) over the last 5 years.
- Over the past 3 years, Heron Therapeutics' Non-Current Debt (Quarterly) stood at $24.3 million in 2023, then rose by 3.14% to $25.0 million in 2024, then spiked by 332.93% to $107.5 million in 2025.
- Its Non-Current Debt was $107.5 million in Q3 2025, compared to $25.2 million in Q1 2025 and $25.0 million in Q4 2024.